Marco Bucci, PhD, Karolinska Institutet, Stockholm, Sweden, presents the results of a study determining the capacity of plasma p-tau217 for predicting amyloid-PET levels in a tertiary memory clinic cohort. p-tau217 has well evidenced diagnostic utility in research settings, but remains understudied in clinical settings. Accordingly, this plasma biomarker, alongside p-tau181, p-tau231, and glial fibrillary protein (GFAP), was quantified in 123 patients admitted to the Clinic for Cognitive Disorders at Karolinska University Hospital. Patients were stratified by disease stage, as determined by clinical assessment, CSF analysis, and amyloid-PET examination. Results showed that, while p-tau217 was the best performing single biomarker across all disease stages, a combinatory approach employing all four biomarkers had a higher predictive value for amyloid-PET+ than using p-tau217 alone. Moving forward, Dr Bucci remarks that analysis of a panel of multiple biomarkers may be the best approach to maximize diagnostic accuracy. This interview took place at the AP/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
